Ascendant Dx - CEO
Omid Moghadam is an innovative scientist, entrepreneur, venture investor and educator. He specializes in launching new ventures with social impact in health and technology.
His latest venture is Ascendant Dx, a diagnostics firm commercializing new ‘omics’ tests for diseases with poor or no existing diagnostic tests. Ascendant’s first product under development, Melody, is an accurate, fast and inexpensive screening test for breast cancer.
Moghadam has inventions in medical imaging, cryptography, microprocessor design, medical devices, diagnostics, digital photography, data science and communications.
He is the founder of Dossia (Health Records), co-founder of Integrated Analytics Solutions (aka Intel Genomics), founder and chairman of CardioWise (Cardiac MRI), board member of NanoWatt Design (Big Data Software), OsteoVantage (Spine Surgery), and The Diary Corporation (HCIT). He serves on the advisory boards of Base Health Corporation (Genomics). Previously, he served as an advisor to Robert Wood Johnson Foundation, Children's Hospital Boston, and California Healthcare Foundation and as a board member at Best Shot Foundation (Childhood Pneumonia), and Health-e Australia Pty (Hospital System).
He holds BS and MS degrees in electrical and computer engineering with emphasis in medical imaging and biophysics and an MBA in finance. He has held academic positions at Harvard Medical School department of biomedical informatics, and Rensselaer Polytechnic Institute Lally School of Business. Mr. Moghadam’s approach to innovation has been highlighted in two books: Grabbing Lightning (2008) and The Innovators Prescription (2008).
Moghadam loves art, history and travel and speaks Farsi, Arabic and German. On Sundays he can be found sweating over FT’s Polymath crossword puzzle.